BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  FDA

  FDA Approves GSK’s Blenrep as Fourth-Line Multiple Myeloma Monotherapy Treatment

  Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.

  August 6, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Biopharma Update on the Novel Coronavirus: August 7

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.

  August 6, 2020

   · 

  3 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  BioSpace Movers & Shakers, Aug. 7

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers.

  August 6, 2020

   · 

  5 min read

   · 

  Alex Keown
• 

  BioCapital

  Clinical Catch-Up: August 3-7

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

  August 6, 2020

   · 

  8 min read

   · 

  Mark Terry
• 

  Business

  Germany’s T-knife Raises $78.4 Million to Develop CAR-T Solid Tumor Therapies

  T-knife GmbH, based in Berlin, Germany, closed a €66 million (about $78.4 million, U.S.) Series A round.

  August 6, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Lundbeck Discontinues Phase II Schizophrenia Study Following Interim Analysis

  Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.

  August 6, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Denali and Biogen Ink Parkinson’s Pact Worth $2.125 Billion

  Biogen and Denali Therapeutics inked a binding deal to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.

  August 6, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  BioMidwest

  Research Roundup: Possible COVID-19 Treatment and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  August 6, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Could Obesity Be Contributing to Severe Cases of COVID-19?

  Although obesity is a known risk factor for death from many conditions, such as cardiovascular disease, experts are now wondering how COVID-19 may impact those who fall into this category.

  August 6, 2020

   · 

  2 min read

   · 

  Krystle Vermes
• 

  Drug Development

  Restoring Cellular Power Outages: A New Drug to Treat Mitochondrial Diseases

  A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.

  August 6, 2020

   · 

  6 min read

   · 

  Chelsea Weidman Burke